Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
Authors
BUSCA, Alessandro, Jon SALMANTON-GARCIA (guarantor), Francesco MARCHESI, Francesca FARINA, Guldane Cengiz SEVAL, Van Doesum JAAP, Nick C DE JONGE, Nathan C BAHR, Johan MAERTENS, Joseph S MELETIADIS, Nicola S FRACCHIOLLA, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Luisa VERGA, Zdenek RACIL, Moraima JIMENEZ, Andreas GLENTHOJ, Ola BLENNOW, Alina Daniela TANASE, Martin SCHOENLEIN, Lucia PREZIOSO, Nina F KHANNA, Rafael F DUARTE, Pavel ZAK, Marcio NUCCI, Marina MACHADO, Austin KULASEKARARAJ, Ildefonso ESPIGADO, De Kort ELIZABETH, Jose-Maria Ribera-Santa SUSANA, Monia MARCHETTI, Gabriele MAGLIANO, Iker FALCES-ROMERO, Osman ILHAN, Emanuele AMMATUNA, Sofia ZOMPI, Panagiotis TSIRIGOTIS, Anastasia ANTONIADOU, Giovanni Paolo Maria ZAMBROTTA, Anna NORDLANDER, Linda Katharina KARLSSON, Michaela HANAKOVA, Giulia DRAGONETTI, Alba CABIRTA, Berg Venemyr CAROLINE, Stefanie GRAEFE, Van Praet JENS, Athanasios TRAGIANNIDIS, Verena PETZER, Alberto LOPEZ-GARCIA, Federico ITRI, Ana GROH, Eleni GAVRIILAKI, Michelina DARGENIO, Laman A RAHIMLI, Oliver A CORNELY and Livio PAGANO
Edition
Frontiers in immunology, LAUSANNE, Frontiers Media S.A. 2023, 1664-3224
BackgroundThe outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. MethodsThis multicenter retrospective study promoted by the European Hematology Association - Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. ResultsThe median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). ConclusionsMortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.
BUSCA, Alessandro, Jon SALMANTON-GARCIA, Francesco MARCHESI, Francesca FARINA, Guldane Cengiz SEVAL, Van Doesum JAAP, Nick C DE JONGE, Nathan C BAHR, Johan MAERTENS, Joseph S MELETIADIS, Nicola S FRACCHIOLLA, Barbora WEINBERGEROVÁ, Luisa VERGA, Zdenek RACIL, Moraima JIMENEZ, Andreas GLENTHOJ, Ola BLENNOW, Alina Daniela TANASE, Martin SCHOENLEIN, Lucia PREZIOSO, Nina F KHANNA, Rafael F DUARTE, Pavel ZAK, Marcio NUCCI, Marina MACHADO, Austin KULASEKARARAJ, Ildefonso ESPIGADO, De Kort ELIZABETH, Jose-Maria Ribera-Santa SUSANA, Monia MARCHETTI, Gabriele MAGLIANO, Iker FALCES-ROMERO, Osman ILHAN, Emanuele AMMATUNA, Sofia ZOMPI, Panagiotis TSIRIGOTIS, Anastasia ANTONIADOU, Giovanni Paolo Maria ZAMBROTTA, Anna NORDLANDER, Linda Katharina KARLSSON, Michaela HANAKOVA, Giulia DRAGONETTI, Alba CABIRTA, Berg Venemyr CAROLINE, Stefanie GRAEFE, Van Praet JENS, Athanasios TRAGIANNIDIS, Verena PETZER, Alberto LOPEZ-GARCIA, Federico ITRI, Ana GROH, Eleni GAVRIILAKI, Michelina DARGENIO, Laman A RAHIMLI, Oliver A CORNELY and Livio PAGANO. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry. Frontiers in immunology. LAUSANNE: Frontiers Media S.A., 2023, vol. 14, February 2023, p. 1-9. ISSN 1664-3224. Available from: https://dx.doi.org/10.3389/fimmu.2023.1125030.
@article{2279455, author = {Busca, Alessandro and SalmantonandGarcia, Jon and Marchesi, Francesco and Farina, Francesca and Seval, Guldane Cengiz and Jaap, Van Doesum and De Jonge, Nick C and Bahr, Nathan C and Maertens, Johan and Meletiadis, Joseph S and Fracchiolla, Nicola S and Weinbergerová, Barbora and Verga, Luisa and Racil, Zdenek and Jimenez, Moraima and Glenthoj, Andreas and Blennow, Ola and Tanase, Alina Daniela and Schoenlein, Martin and Prezioso, Lucia and Khanna, Nina F and Duarte, Rafael F and Zak, Pavel and Nucci, Marcio and Machado, Marina and Kulasekararaj, Austin and Espigado, Ildefonso and Elizabeth, De Kort and Susana, JoseandMaria RiberaandSanta and Marchetti, Monia and Magliano, Gabriele and FalcesandRomero, Iker and Ilhan, Osman and Ammatuna, Emanuele and Zompi, Sofia and Tsirigotis, Panagiotis and Antoniadou, Anastasia and Zambrotta, Giovanni Paolo Maria and Nordlander, Anna and Karlsson, Linda Katharina and Hanakova, Michaela and Dragonetti, Giulia and Cabirta, Alba and Caroline, Berg Venemyr and Graefe, Stefanie and Jens, Van Praet and Tragiannidis, Athanasios and Petzer, Verena and LopezandGarcia, Alberto and Itri, Federico and Groh, Ana and Gavriilaki, Eleni and Dargenio, Michelina and Rahimli, Laman A and Cornely, Oliver A and Pagano, Livio}, article_location = {LAUSANNE}, article_number = {February 2023}, doi = {http://dx.doi.org/10.3389/fimmu.2023.1125030}, keywords = {allogeneic HSCT; COVID-19 infection; immunocompromised patients; SARS-CoV-2; hematological malignances}, language = {eng}, issn = {1664-3224}, journal = {Frontiers in immunology}, title = {Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry}, url = {https://www.frontiersin.org/articles/10.3389/fimmu.2023.1125030/full}, volume = {14}, year = {2023} }
TY - JOUR ID - 2279455 AU - Busca, Alessandro - Salmanton-Garcia, Jon - Marchesi, Francesco - Farina, Francesca - Seval, Guldane Cengiz - Jaap, Van Doesum - De Jonge, Nick C - Bahr, Nathan C - Maertens, Johan - Meletiadis, Joseph S - Fracchiolla, Nicola S - Weinbergerová, Barbora - Verga, Luisa - Racil, Zdenek - Jimenez, Moraima - Glenthoj, Andreas - Blennow, Ola - Tanase, Alina Daniela - Schoenlein, Martin - Prezioso, Lucia - Khanna, Nina F - Duarte, Rafael F - Zak, Pavel - Nucci, Marcio - Machado, Marina - Kulasekararaj, Austin - Espigado, Ildefonso - Elizabeth, De Kort - Susana, Jose-Maria Ribera-Santa - Marchetti, Monia - Magliano, Gabriele - Falces-Romero, Iker - Ilhan, Osman - Ammatuna, Emanuele - Zompi, Sofia - Tsirigotis, Panagiotis - Antoniadou, Anastasia - Zambrotta, Giovanni Paolo Maria - Nordlander, Anna - Karlsson, Linda Katharina - Hanakova, Michaela - Dragonetti, Giulia - Cabirta, Alba - Caroline, Berg Venemyr - Graefe, Stefanie - Jens, Van Praet - Tragiannidis, Athanasios - Petzer, Verena - Lopez-Garcia, Alberto - Itri, Federico - Groh, Ana - Gavriilaki, Eleni - Dargenio, Michelina - Rahimli, Laman A - Cornely, Oliver A - Pagano, Livio PY - 2023 TI - Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry JF - Frontiers in immunology VL - 14 IS - February 2023 SP - 1-9 EP - 1-9 PB - Frontiers Media S.A. SN - 16643224 KW - allogeneic HSCT KW - COVID-19 infection KW - immunocompromised patients KW - SARS-CoV-2 KW - hematological malignances UR - https://www.frontiersin.org/articles/10.3389/fimmu.2023.1125030/full N2 - BackgroundThe outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. MethodsThis multicenter retrospective study promoted by the European Hematology Association - Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. ResultsThe median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). ConclusionsMortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection. ER -
BUSCA, Alessandro, Jon SALMANTON-GARCIA, Francesco MARCHESI, Francesca FARINA, Guldane Cengiz SEVAL, Van Doesum JAAP, Nick C DE JONGE, Nathan C BAHR, Johan MAERTENS, Joseph S MELETIADIS, Nicola S FRACCHIOLLA, Barbora WEINBERGEROVÁ, Luisa VERGA, Zdenek RACIL, Moraima JIMENEZ, Andreas GLENTHOJ, Ola BLENNOW, Alina Daniela TANASE, Martin SCHOENLEIN, Lucia PREZIOSO, Nina F KHANNA, Rafael F DUARTE, Pavel ZAK, Marcio NUCCI, Marina MACHADO, Austin KULASEKARARAJ, Ildefonso ESPIGADO, De Kort ELIZABETH, Jose-Maria Ribera-Santa SUSANA, Monia MARCHETTI, Gabriele MAGLIANO, Iker FALCES-ROMERO, Osman ILHAN, Emanuele AMMATUNA, Sofia ZOMPI, Panagiotis TSIRIGOTIS, Anastasia ANTONIADOU, Giovanni Paolo Maria ZAMBROTTA, Anna NORDLANDER, Linda Katharina KARLSSON, Michaela HANAKOVA, Giulia DRAGONETTI, Alba CABIRTA, Berg Venemyr CAROLINE, Stefanie GRAEFE, Van Praet JENS, Athanasios TRAGIANNIDIS, Verena PETZER, Alberto LOPEZ-GARCIA, Federico ITRI, Ana GROH, Eleni GAVRIILAKI, Michelina DARGENIO, Laman A RAHIMLI, Oliver A CORNELY and Livio PAGANO. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry. \textit{Frontiers in immunology}. LAUSANNE: Frontiers Media S.A., 2023, vol.~14, February 2023, p.~1-9. ISSN~1664-3224. Available from: https://dx.doi.org/10.3389/fimmu.2023.1125030.